Literature DB >> 2552845

Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats.

K P Conrad1, K A Vernier.   

Abstract

We postulated that guanosine 3',5'-cyclic monophosphate (cGMP), a cellular mediator of vascular smooth muscle relaxation, might mediate maternal renal and cardiovascular hemodynamic adaptation to pregnancy. Because extracellular levels of cGMP most likely reflect intracellular production, we began our investigation of this hypothesis by measuring the plasma concentration, urinary excretion, and metabolic clearance rates of cGMP during pregnancy in rats. Plasma cGMP was significantly elevated during mid- and late pregnancy, whereas urinary excretion of cGMP was increased throughout pregnancy. The fractional excretion of cGMP by the kidneys was 0.90 +/- 0.15 in the nonpregnant condition. In contrast, plasma levels of adenosine 3',5'-cyclic monophosphate were unchanged during pregnancy, and its urinary excretion rose slightly, reaching significance only on gestational day 20. There was also a significant rise in urinary excretion of cGMP throughout pseudopregnancy. The metabolic clearance rate of cGMP measured in chronically instrumented rats before, during, and after pregnancy was not significantly altered during gestation. The elevated plasma level of cGMP during gestation in rats, in the face of an unchanged metabolic clearance, reflects augmented tissue(s) production of cGMP, although enhanced cellular efflux may contribute. Because cGMP is a second messenger for several vasodilatory hormones, our data are consistent with the hypothesis that vascular production of cGMP may increase during pregnancy and thereby contribute to maternal renal and cardiovascular vasodilation. (Most investigators have not observed increment of plasma atrial natriuretic peptide in rat gestation; therefore this hormone is an unlikely first messenger for the elevated extracellular levels of cGMP that we have observed. Finally, pseudopregnant rats also showed enhanced urinary excretion of cGMP, which suggests that the proliferative activity that accompanies fetoplacental maturation, as well as hormones elaborated by the fetoplacental unit, is not necessary for the rise in urinary excretion of cGMP observed during pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552845     DOI: 10.1152/ajpregu.1989.257.4.R847

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  22 in total

1.  Relaxin is a potent renal vasodilator in conscious rats.

Authors:  L A Danielson; O D Sherwood; K P Conrad
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

2.  Relaxin is essential for renal vasodilation during pregnancy in conscious rats.

Authors:  J Novak; L A Danielson; L J Kerchner; O D Sherwood; R J Ramirez; P A Moalli; K P Conrad
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 3.  Impact of pregnancy on underlying renal disease.

Authors:  Chris Baylis
Journal:  Adv Ren Replace Ther       Date:  2003-01

Review 4.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

5.  Nitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation.

Authors:  C R Rosenfeld; B E Cox; T Roy; R R Magness
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

6.  Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats.

Authors:  L A Danielson; K P Conrad
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 7.  Maternal vasodilation in pregnancy: the emerging role of relaxin.

Authors:  Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

8.  Domain-Specific Partitioning of Uterine Artery Endothelial Connexin43 and Caveolin-1.

Authors:  Bryan C Ampey; Timothy J Morschauser; Jayanth Ramadoss; Ronald R Magness
Journal:  Hypertension       Date:  2016-08-29       Impact factor: 10.190

9.  Mechanisms of vasodilatation in pregnancy: studies of the role of prostaglandins and nitric-oxide in changes of vascular reactivity in the in situ blood perfused mesentery of pregnant rats.

Authors:  Z M Chu; L J Beilin
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

Review 10.  Vasodilator factors in the systemic and local adaptations to pregnancy.

Authors:  Gloria Valdes; Peter Kaufmann; Jenny Corthorn; Rafaela Erices; K Bridget Brosnihan; Janae Joyner-Grantham
Journal:  Reprod Biol Endocrinol       Date:  2009-07-31       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.